In contemporary oncology, we see the lack of appropriate patient stratification, resulting in drugs often being administered to patients without producing any benefit. This single problem has important consequences such as:
- up to 90% failure rates in clinical trials
- clinical development cost of about 1 bilion dollars per newly approved drug
- growing cost for patient treatment, typically in the range of 10-100 thousand dollars
- reimbursement issues, with up to 75% drugs not accessible in some countries because of their cost
- poor clinical response, with up to 90% failure rates for some cancer types
Such issues still remain despite the development of genetic biomarkers and molecular profiling of the patient.